ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 530,72
0,00%
Dow Jones
39 164,06
0,09%
DAX
18 210,55
0,26%
Brent Oil
85,695
0,33%
Bitcoin
61 483,61
-0,21%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. La Jolla Pharmaceutical Company (LJPC)

  7. La Jolla Pharmaceutical Company (LJPC) Actualités

LJPC

La Jolla Pharmaceutical (LJPC)

La Jolla Pharmaceutical Company
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LJPC
DateHeureSourceTitreSymboleSociété
14/02/202316h07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
01/09/202214h39Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:LJPCLa Jolla Pharmaceutical Company
29/08/202218h31Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
29/08/202218h10Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:LJPCLa Jolla Pharmaceutical Company
23/08/202223h01Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h32Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h20Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202215h09Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
22/08/202214h55Business WireInnoviva Completes Acquisition of La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company
15/08/202214h04Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LJPCLa Jolla Pharmaceutical Company
25/07/202214h40Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:LJPCLa Jolla Pharmaceutical Company
25/07/202214h35Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:LJPCLa Jolla Pharmaceutical Company
12/07/202212h10Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:LJPCLa Jolla Pharmaceutical Company
11/07/202221h47Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:LJPCLa Jolla Pharmaceutical Company
11/07/202213h32Business WireInnoviva to Acquire La Jolla Pharmaceutical CompanyNASDAQ:LJPCLa Jolla Pharmaceutical Company
05/07/202223h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LJPCLa Jolla Pharmaceutical Company
16/05/202222h15Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate ProgressNASDAQ:LJPCLa Jolla Pharmaceutical Company
09/03/202214h15Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate ProgressNASDAQ:LJPCLa Jolla Pharmaceutical Company
09/03/202214h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:LJPCLa Jolla Pharmaceutical Company
17/11/202114h00Business WireLa Jolla Pharmaceutical Company Announces Share Repurchase PlanNASDAQ:LJPCLa Jolla Pharmaceutical Company
04/11/202113h45Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate ProgressNASDAQ:LJPCLa Jolla Pharmaceutical Company
02/11/202114h14Edgar (US Regulatory)Notification That a Class of Securities of Successor Issuer Is Demed to Be Registered Pursuant to Section 12(b) (8-k12b)NASDAQ:LJPCLa Jolla Pharmaceutical Company
10/09/202114h00Business WireTony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical CompanyNASDAQ:LJPCLa Jolla Pharmaceutical Company
05/08/202114h30Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate ProgressNASDAQ:LJPCLa Jolla Pharmaceutical Company
04/06/202113h16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
04/06/202113h06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
25/05/202123h06Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:LJPCLa Jolla Pharmaceutical Company
07/05/202114h45Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 & Highlights Corporate ...NASDAQ:LJPCLa Jolla Pharmaceutical Company
08/03/202114h55Business WireLa Jolla Pharmaceutical Company Announces Financial Results for the Three & Twelve Months Ended December 31, 2020 & Highlight...NASDAQ:LJPCLa Jolla Pharmaceutical Company
 Showing the most relevant articles for your search:NASDAQ:LJPC

Dernières Valeurs Consultées

BIT
1HPE
Hewlett Packard Enterprise
COIN
BIFIIUSD
BiFi
BIT
UC2DQN
Unicredit Bank
TG
IOB
Ion Beam Applications
BIT
P210A0
NLBNPIT210A0 20351221 12...
ASX
MICH
Magellan Infrastructure
BIT
P1ZSW4
NLBNPIT1ZSW4 20240621 22
BOV
HAPV99F
HAPVIDA
BOV
SNEC34R
Sony
BOV
BALM4R
BAUMER PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés